PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31142283-2	2019	However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known.	Tenofovir	76-85	HCC	Homo sapiens	53-56	
31142283-3	2019	This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes.	Tenofovir	86-95	HCC	Homo sapiens	72-75	
31142283-9	2019	CONCLUSION: There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients.	Tenofovir	40-49	HCC	Homo sapiens	62-65	
31142283-9	2019	CONCLUSION: There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients.	Tenofovir	108-117	HCC	Homo sapiens	62-65	
30267080-3	2019	Objective: To compare entecavir and tenofovir in terms of the risk of HCC and death or liver transplant in patients with CHB infection.	Tenofovir	36-45	HCC	Homo sapiens	70-73	
30267080-10	2019	In the population cohort, the annual incidence rate of HCC was significantly lower in the tenofovir group (0.64 per 100 person-years [PY]) than in the entecavir group (1.06 per 100 PY).	Tenofovir	90-99	HCC	Homo sapiens	55-58	
30267080-11	2019	By multivariable-adjusted analysis, tenofovir therapy was associated with a significantly lower risk of HCC (hazard ratio [HR], 0.61; 95% CI, 0.54-0.70) and all-cause mortality or transplant (HR, 0.77; 95% CI, 0.65-0.92) compared with entecavir.	Tenofovir	36-45	HCC	Homo sapiens	104-107	
30267080-12	2019	The tenofovir group also showed a significantly lower risk of HCC in the 10 923-pair propensity score-matched population cohort (HR, 0.62; 95% CI, 0.54-0.70) and 869-pair propensity score-matched hospital cohort (HR, 0.68; 95% CI, 0.46-0.99) compared with the entecavir group.	Tenofovir	4-13	HCC	Homo sapiens	62-65	
30267080-13	2019	Conclusions and Relevance: This study suggests that tenofovir treatment was associated with a significantly lower risk of HCC compared with entecavir treatment in a population-based cohort of adults with CHB; these findings were validated in a hospital cohort.	Tenofovir	52-61	HCC	Homo sapiens	122-125	
30181772-0	2018	Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis.	Tenofovir	0-29	HCC	Homo sapiens	50-53	
30181772-9	2018	The cumulative probability of HCC development in TDF-contained group were significantly lower than it in non-TDF-contained group (p < 0.05).	Tenofovir	49-52	HCC	Homo sapiens	30-33	
30181772-9	2018	The cumulative probability of HCC development in TDF-contained group were significantly lower than it in non-TDF-contained group (p < 0.05).	Tenofovir	109-112	HCC	Homo sapiens	30-33